Fagron N.V. Logo

Fagron N.V.

A global pharmaceutical compounding company focused on personalized medicine.

FAGR | BR

Overview

Corporate Details

ISIN(s):
BE0003874915
LEI:
549300TRKRUFK2RRG779
Country:
Belgium
Address:
Venecoweg 20A, 9810 Nazareth

Description

Fagron N.V. is a global company active in pharmaceutical compounding, focusing on the delivery of personalized medicine. The company optimizes and innovates compounding to widen the therapeutic options for prescribers worldwide. Fagron develops, markets, and distributes pharmaceutical raw materials, equipment, and specially formulated vehicles and bases, such as the Pentravan® transdermal base and the SyrSpend® range of oral suspending vehicles. Its primary customers are hospitals, pharmacies, and clinics. The company also operates in the field of genomics to further support personalized healthcare solutions.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2022-10-28 18:00
AOC - Transparency notification Fagron 27 October 2022.pdf
English 109.8 KB
2022-10-28 18:00
Disclosure of notification received from Active Ownership Corporation Sarl.pdf
English 103.3 KB
2022-10-28 18:00
Openbaarmaking van kennisgeving ontvangen van Active Ownership Corporation Sarl…
Dutch 105.2 KB
2022-10-13 07:30
Fagron delivers topline growth of 21.5% to €173 million
Dutch 175.3 KB
2022-10-13 07:30
Fagron delivers topline growth of 21.5% to €173 million
English 229.0 KB
2022-10-13 07:00
Fagron delivers topline growth of 21.5% to €173 million.pdf
English 244.3 KB
2022-10-13 07:00
Fagron realiseert omzetgroei van 21,5% naar €173 miljoen.pdf
Dutch 189.8 KB
2022-09-27 08:10
Fagron commits to set science-based emission reduction targets
English 94.5 KB
2022-09-27 08:10
Fagron commits to set science-based emission reduction targets
English 125.5 KB
2022-09-21 14:12
Disclosure of notification received from Templeton Investment Counsel, LLC
English 100.2 KB
2022-09-21 14:12
Disclosure of notification received from Templeton Investment Counsel, LLC
English 102.1 KB
2022-09-20 19:00
Fagron TR-1BE-ENG 09.14.2022_issuer.pdf
English 235.5 KB
2022-09-20 19:00
Disclosure of notification received from Templeton Investment Counsel, LLC.pdf
English 102.1 KB
2022-09-20 19:00
Openbaarmaking van kennisgeving ontvangen van Templeton Investment Counsel, LLC…
Dutch 100.2 KB
2022-09-05 07:44
Disclosure of received notification of Kabouter Management LLC
English 102.4 KB

Automate Your Workflow. Get a real-time feed of all Fagron N.V. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Fagron N.V.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Fagron N.V. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-05-23 Pulido Andrew Executive member Sell 85,000 1,803,351.50 EUR
2025-05-22 Pulido Andrew Executive member Buy 85,000 1,617,550.00 EUR
2025-05-02 De Jong Cornelia Neeltje Board Sell 12,689 263,834.55 EUR
2025-04-30 De Jong Cornelia Neeltje Board Sell 229 4,660.15 EUR
2025-04-29 De Jong Cornelia Neeltje Board Sell 10,000 201,500.00 EUR
2025-03-28 J. Verlinden Other Buy 24,551 453,702.48 EUR
2025-03-28 J. Verlinden Other Sell 17,930 344,047.56 EUR
2025-03-27 Padilla Rafael Board Buy 78,469 1,450,107.12 EUR
2025-03-27 De Jong Cornelia Neeltje Board Buy 45,418 839,324.64 EUR
2025-02-21 Bakker Vera Executive member Buy 773 15,000.00 EUR

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.